Novel 5-MeO-DMT Formulation BPL-003

Beckley Psytech Ltd, the private, clinical-stage biopharmaceutical company dedicated to improving the lives of people living with neuropsychiatric disorders by developing effective and rapid-acting psychedelic medicines, today announced the publication of a new paper in The Journal of Psychopharmacology which demonstrates the safety, tolerability and rapid-acting subjective effects of BPL-003, Beckley Psytech’s novel, synthetic, intranasal benzoate salt formulation of 5-MeO-DMT (also known as mebufotenin). 

Read more

Psychological Flexibility and Psychedelics

In a new study, researchers found that psychological flexibility, several facets of mindfulness, and values-congruent living significantly improved following psilocybin and were maintained through week 16.

Additionally, improvements in psychological flexibility and experiential acceptance were strongly associated with reductions in depression severity following psilocybin.

Keep reading for the full article at Nature.com

Read more

Psychedelics, Psychosis and Manic Symptoms

A new study analyzed data from the Swedish Twin Registry, a national dataset that includes self-reported drug use and psychotic and manic symptom occurrence.

The researchers’ analyses found no significant association between psychedelic use and psychotic symptoms, but in comparing identical twin pairs in which one had taken psychedelics while the other had not, the twin who’d tried psychedelics was more likely to report experiencing manic symptoms.

In the twin data researchers reviewed, mania was also strongly correlated with a genetic predisposition to schizophrenia and to bipolar I disorder.

In other words, those who experienced manic symptoms after psychedelic use may have been more genetically prone to mental illnesses.

Read more